Cas9 nickase-mediated contraction of CAG/CTG repeats at multiple disease loci

Alvaro Murillo,Melanie Alpaugh,Meghan Larin,Emma L. Randall,Laura Heraty,Ruban Rex Durairaj,Alys N. Aston,Alysha S. Taylor,Alex Mas Monteys,Nina Stöberl,Aeverie E. R. Heuchan,Pascale Aeschlimann,Soumyasree Bhattacharyya,Nicholas D. Allen,Jack Puymirat,Beverly L. Davidson,Francesca Cicchetti,Mariah Lelos,Vincent Dion

DOI: https://doi.org/10.1101/2024.02.19.580669

2024-02-21

Abstract:Expanded CAG/CTG repeats cause at least 15 different neurodegenerative and neuromuscular diseases that all remain without an effective disease modifying treatment. Because the size of the repeat tract accounts for the majority of the variation in disease severity, contracting them presents an attractive therapeutic avenue. Here, we show that the CRISPR-Cas9 nickase targeting the CAG/CTG repeat itself leads to efficient contractions in Huntington’s disease patient-derived neurons and astrocytes, as well as in myotonic dystrophy type 1 patient-derived neurons. Using single-cell DNA sequencing, PCR-free whole genome sequencing, and targeted long-read sequencing of the locus, we found no off-target mutations above background in neurons and astrocytes. Furthermore, we delivered the Cas9 nickase and sgRNA stereotactically to a mouse model of Huntington’s disease using adeno-associated viruses, and found contractions accumulating in over half of the infected cells over a period of 5 months. We also found that the Cas9 nickase was prone to silencing, further improving the safety of the approach. Our results provide the proof of concept for using the Cas9 nickase to contract the repeat tract safely in multiple cell types and diseases.

Neuroscience

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: How to effectively contract CAG/CTG repeat sequences that cause multiple neurodegenerative and neuromuscular diseases using the CRISPR - Cas9 nickase technology, while avoiding off - target mutations and other potential safety issues. Specifically, the paper focuses on at least 15 different neurodegenerative and neuromuscular diseases caused by abnormal expansion of CAG/CTG repeat sequences in genes, such as Huntington's disease (HD) and myotonic dystrophy type 1 (DM1). There are currently no effective treatments for these diseases. By using CRISPR - Cas9 nickase directly targeting these repeat sequences, the paper shows that in neurons and astrocytes derived from Huntington's disease patients and neurons derived from myotonic dystrophy type 1 patients, it effectively induces the contraction of repeat sequences, and no off - target mutations above the background level are detected. In addition, the study also delivers Cas9 nickase and sgRNA to Huntington's disease mouse models by stereotactic injection of adeno - associated viruses (AAVs), observes the contraction of repeat sequences in more than half of the infected cells, and finds that Cas9 nickase is silenced, further improving the safety of this method. In conclusion, this study provides a proof - of - concept, demonstrating that Cas9 nickase can safely contract repeat sequences in multiple cell types and diseases, providing new ideas for treating these diseases.

Cas9 nickase-mediated contraction of CAG/CTG repeats at multiple disease loci

Precise CAG repeat contraction in a Huntington’s Disease mouse model is enabled by gene editing with SpCas9-NG

CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro

Dual-targeting CRISPR-CasRx reduces ALS/FTD sense and antisense repeat RNAs in vitro and in vivo

Amplification-free, CRISPR-Cas9 Targeted Enrichment and SMRT Sequencing of Repeat-Expansion Disease Causative Genomic Regions

CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA

Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Identification of genetic modifiers of Huntington′s disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Cas9-mediated Replacement of Expanded CAG Repeats in a Pig Model of Huntington’s Disease

Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease

An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair

Lack of RAN-mediated Toxicity in Huntington's Disease Knock-in Mice.

TALEN-induced contraction of CTG trinucleotide repeats in myotonic dystrophy type 1 cells

Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo

Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model

In vivo CRISPR base editing for treatment of Huntington′s disease

CRISPR interference to evaluate modifiers of C9ORF72-mediated toxicity in FTD

Cas9 editing of ATXN1 in a spinocerebellar ataxia type 1 mice and human iPSC-derived neurons

Splice modulators target PMS1 to reduce somatic expansion of the Huntington’s disease-associated CAG repeat